Abstract: The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.
Type:
Grant
Filed:
May 9, 2019
Date of Patent:
April 23, 2024
Assignee:
Novartis AG
Inventors:
John Louis Diener, Jiaping Gao, Rick Jerome Schiebinger
Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.
Type:
Grant
Filed:
January 26, 2018
Date of Patent:
April 16, 2024
Assignee:
Surrozen Operating, Inc.
Inventors:
Zhengjian Zhang, Jennifer Jean Brady, Aaron Ken Sato, Wen-Chen Yeh, Yang Li, Teppei Yamaguchi
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
Type:
Grant
Filed:
September 10, 2021
Date of Patent:
April 9, 2024
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Achal Pashine, Michael L Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
Abstract: The present invention is directed towards isolated antibodies that bind to IL12R?1. Specifically, anti-IL12R?1 antibodies, and methods of treatment using the antibodies are disclosed. The antibody is targeted against the beta 1 subunit of the receptors of IL-12 and IL-23 and is capable of blocking signaling by inflammatory cytokines IL-12 and IL-23, which could be useful in treating autoimmune inflammatory diseases, such as inflammatory bowel disease (IBD), RA, and psoriasis.
Type:
Grant
Filed:
December 9, 2021
Date of Patent:
April 9, 2024
Assignee:
Washington University
Inventors:
Marco Colonna, Cristiane Secca da Silva
Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Type:
Grant
Filed:
August 24, 2021
Date of Patent:
April 2, 2024
Assignee:
Novartis AG
Inventors:
Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
Type:
Grant
Filed:
September 10, 2021
Date of Patent:
March 5, 2024
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
Abstract: The invention provides antibodies that specifically bind to an epitope containing N-acetylglucosamine and specifically bind to an epitope comprising N-acetyl-galactosamine expressed by a cancer cell or an inflammatory cell. Further provided are methods for treating gastrointestinal diseases characterized by inflammatory cells in the intestines or colon in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine and specifically binds to an epitope comprising N-acetyl-galactosamine.
Abstract: Provided herein are methods of treating eye disorders by administering an anti-VEGF antibody and/or conjugate to a subject having an eye disorder. The anti-VEGF antibody of the present disclosure may be an anti-VEGF antibody conjugate that includes a polymeric moiety that extends the half-life/effectiveness/properties of the antibody when administered to a subject. A method of the present disclosure includes administering one or more doses of an anti-VEGF antibody conjugate to a subject (e.g., human or other mammalian patient) in need of treating an eye disorder, where the anti-VEGF antibody conjugate may be administered less frequently than a standard anti-VEGF therapy to treat the eye disorder.
Type:
Grant
Filed:
October 9, 2020
Date of Patent:
February 27, 2024
Assignee:
Kodiak Sciences Inc.
Inventors:
Jason Ehrlich, Pablo Velazquez-Martin, Joel Naor, Daniel Victor Perlroth, Hong Liang
Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets.
Type:
Grant
Filed:
September 26, 2022
Date of Patent:
February 20, 2024
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS CITÉ, SORBONNE UNIVERSITÉ
Inventors:
Guido Kroemer, José Manuel Bravo San Pedro
Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
Type:
Grant
Filed:
August 13, 2020
Date of Patent:
February 13, 2024
Assignee:
Shattuck Labs, Inc.
Inventors:
Taylor Schreiber, George Fromm, Suresh De Silva
Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases.
Type:
Grant
Filed:
June 14, 2018
Date of Patent:
January 23, 2024
Assignee:
Kymab Limited
Inventors:
Martina Rauner, Lorenz C. Hofbauer, Uwe Platzbecker, Ulrike Baschant
Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.
Type:
Grant
Filed:
April 13, 2021
Date of Patent:
January 16, 2024
Assignees:
ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.
Inventors:
Yasufumi Murakami, Shigeki Mukoubata, Hirotada Akiyama, Koji Konomi
Abstract: Disclosed herein are compositions including an inhibitor of extracellular human metallothionein (MT) and a pancreatic targeting moiety linked to the inhibitor of extracellular human MT.
Type:
Grant
Filed:
January 17, 2019
Date of Patent:
January 9, 2024
Assignees:
UNIVERSITY OF CONNECTICUT, JOSLIN DIABETES CENTER, INC.
Inventors:
Michael A. Lynes, Yu-Hua Tseng, Matthew D. Lynes
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Abstract: The present disclosure relates to an antibody against Aquaporin-4 (AQP4). These peptide-specific AQP4 antibodies play a role to create a NMO model and contribute for investigating the NMO disease mechanisms and developing the strategy of the treatment.
Abstract: Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.
Type:
Grant
Filed:
June 13, 2018
Date of Patent:
December 19, 2023
Assignee:
DINGFU BIOTARGET CO., LTD.
Inventors:
Ting Xu, Yan Luan, Jianjian Peng, Kai Fu, Meng Zhao, Xiaoxiao Wang
Abstract: The present invention relates to treatment of cancer using agonist anti-MET antibodies or fragments thereof. In particular, the invention relates to treatment of colorectal cancer using agonist anti-MET antibodies or fragments, typically colorectal cancer associated with chronic inflammation and/or gene mutations in the colon and in the gastrointestinal tract in general. The invention further relates to treating intestinal fibrosis using agonist anti-MET antibodies.
Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
Type:
Grant
Filed:
April 22, 2021
Date of Patent:
November 28, 2023
Assignee:
OncoResponse, Inc.
Inventors:
Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst